SZABO SCANDIC

Part of Europa Biosite

# Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

## Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

## Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand


**SZABO-SCANDIC HandelsgmbH**

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

# NVP-BVU972

| | |
|---|---|
| **Cat. No.:** | HY-15456 |
| **CAS No.:** | 1185763-69-2 |
| **Molecular Formula:** | $C_{20}H_{16}N_6$ |
| **Molecular Weight:** | 340.38 |
| **Target:** | c-Met/HGFR |
| **Pathway:** | Protein Tyrosine Kinase/RTK |
| **Storage:** | Powder -20°C 3 years<br>4°C 2 years<br>In solvent -80°C 2 years<br>-20°C 1 year |



## SOLVENT & SOLUBILITY

**In Vitro**

DMSO : 100 mg/mL (293.79 mM; Need ultrasonic)

| Preparing Stock Solutions | Solvent / Mass / Concentration | 1 mg | 5 mg | 10 mg |
|---|---|---|---|---|
| | 1 mM | 2.9379 mL | 14.6895 mL | 29.3789 mL |
| | 5 mM | 0.5876 mL | 2.9379 mL | 5.8758 mL |
| | 10 mM | 0.2938 mL | 1.4689 mL | 2.9379 mL |

Please refer to the solubility information to select the appropriate solvent.

**In Vivo**

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (7.34 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (7.34 mM); Clear solution

## BIOLOGICAL ACTIVITY

**Description**

NVP-BVU972 is an selective and potent Met inhibitor, with an $IC_{50}$ of 14 nM. NVP-BVU972 also exhibits good anti-proliferative activity against Met with drug-resistant mutations and inhibits phosphorylation. NVP-BVU972 can be used in study of cancer [1].

**In Vitro**

NVP-BVU972 (600 nM-9.6 μM; 72 h) shows good antiproliferative activity to BaF3 cells with MET mutations[1].
NVP-BVU972 (0-10 μM; 2 h) reduces TPR-MET phosphorylation in a dose-dependent manner in BaF3 TPR-MET cells[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[1]

| | |
|---|---|
| Cell Line: | BaF3 TPR-MET cells |
| Concentration: | 600 nM-9.6 μM |
| Incubation Time: | 72 h |
| Result: | Exhibited good antiproliferative effect on BaF3 cells with MET mutations, showed $IC_{50}$s of 1.2, 3.6, 14.1, 14.6, 31.5, >129 and >129 nM for M1211L, M1250T, F1200I, V1155L, L1195V, D1228A and Y1230H mutations, respectively.<br>Showed antiproliferative effect on BaF3 cells containing wild-type (WT) TPR-MET, with an $IC_{50}$ of 77 nM. |

Western Blot Analysis[1]

| | |
|---|---|
| Cell Line: | BaF3 TPR-MET cells |
| Concentration: | 0, 0.01, 0.1, 1, 10 μM |
| Incubation Time: | 2 h |
| Result: | Inhibited phosphorylation of TPR-MET in a dose-dependent manner. |

## REFERENCES

[1]. Tiedt, Ralph, et al. A Drug Resistance Screen Using a Selective MET Inhibitor Reveals a Spectrum of Mutations That Partially Overlap with Activating Mutations Found in Cancer Patients. Cancer Research (2011), 71(15), 5255-5264.



Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA